{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:05:34Z","timestamp":1789013134900,"version":"build-2803163510"},"reference-count":12,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Although Dara\u2013VCD (daratumumab\u2013bortezomib\u2013cyclophosphamide\u2013dexamethasone) has revolutionized the treatment of newly diagnosed Amyloid Light chain (AL) amyloidosis, patients with stage IIIb disease were excluded in the pivotal trial. We performed a multicentre retrospective cohort study to investigate the outcomes of 19 consecutive patients treated with Dara\u2013VCD front\u2010line therapy who had stage IIIb AL at diagnosis. More than two thirds presented with New York Heart Association Class III\/IV symptoms, and had a median of two organs involved (range, 2\u20134). The haematologic overall response rate was 100%, with 17\/19 patients (89.5%) achieving a very good partial response (VGPR) or better. Haematologic responses were achieved rapidly, as evidenced by 63% of evaluable patients with involved serum free light chains (iFLC)\u2009&lt;\u20092\u00a0mg\/dl and the difference between involved and uninvolved serum free light chains (dFLC)\u00a0&lt;1\u00a0mg\/dl at three months. Among 18 evaluable patients, 10 (56%) achieved a cardiac organ response and six (33%) cardiac VGPR or better. The median time to first cardiac response was 1.9\u00a0months (range, 0.4\u20137.3). At a median follow\u2010up of 12\u2009months for surviving patients, estimated one\u2010year overall survival was 67.5% [95% confidence interval (CI), 43.8\u201384.7]. The incidence of grade 3 or higher infections was 21%, with no infection\u2010related mortality thus far. In summary, Dara\u2013VCD has a promising efficacy and safety profile in stage IIIb AL, and should be studied in prospective trials.<\/jats:p>","DOI":"10.1111\/bjh.18733","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T08:16:22Z","timestamp":1678436182000},"page":"913-916","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["First report of outcomes in patients with stage I<scp>IIb AL<\/scp> amyloidosis treated with <scp>Dara\u2013VCD<\/scp> front\u2010line therapy"],"prefix":"10.1111","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-3003","authenticated-orcid":false,"given":"Rajshekhar","family":"Chakraborty","sequence":"first","affiliation":[{"name":"Myeloma\/Amyloidosis Program, Herbert Irving Comprehensive Cancer Center Columbia University Irving Medical Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3576-9106","authenticated-orcid":false,"given":"Cara","family":"Rosenbaum","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology Weill Cornell Medicine  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurbakhash","family":"Kaur","sequence":"additional","affiliation":[{"name":"Harold C. Simmons Comprehensive Cancer Center, Utah Southwestern Medical Center  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5482-7543","authenticated-orcid":false,"given":"Divaya","family":"Bhutani","sequence":"additional","affiliation":[{"name":"Myeloma\/Amyloidosis Program, Herbert Irving Comprehensive Cancer Center Columbia University Irving Medical Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai","family":"Radhakrishnan","sequence":"additional","affiliation":[{"name":"Division of Nephrology Columbia University  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus Y.","family":"Mapara","sequence":"additional","affiliation":[{"name":"Myeloma\/Amyloidosis Program, Herbert Irving Comprehensive Cancer Center Columbia University Irving Medical Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Maurer","sequence":"additional","affiliation":[{"name":"Cardiac Amyloidosis Program Columbia University Irving Medical Center, New York Presbyterian Hospital  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[{"name":"Myeloma\/Amyloidosis Program, Herbert Irving Comprehensive Cancer Center Columbia University Irving Medical Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.029"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-473066"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-141604"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028631"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.7614"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20381"},{"issue":"7","key":"e_1_2_8_8_1","article-title":"Graded cardiac response criteria for patients with systemic light chain amyloidosis","volume":"41","author":"Muchtar E","year":"2022","journal-title":"J Clin Onco"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016348"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.178095"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-168757"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157044"},{"key":"e_1_2_8_13_1","first-page":"1","article-title":"Guidelines for non\u2010transplant chemotherapy for treatment of systemic AL amyloidosis: EHA\u2010ISA working group","volume":"1","author":"Wechalekar AD","year":"2022","journal-title":"Amyloid"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18733","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.18733","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T04:07:20Z","timestamp":1713240440000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,10]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1111\/bjh.18733"],"URL":"https:\/\/doi.org\/10.1111\/bjh.18733","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,10]]},"assertion":[{"value":"2022-12-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}